Clinical trials: Vitiligo
Vitiligo, Generalized
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo
The study aims to evaluate the safety and efficacy of the combination of topical baricitinib and 308-nm monochromatic excimer light versus 308-nm monochromatic excimer light alone in treatment of non-segmental vitiligo.
- Trial name
- NCT05950542
- Testing
- Baricitinib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Vitiligo
The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.
The goal of this clinical trial is to learn if adding mini-oral pulse steroid therapy improves the results of non-cultured epidermal cell suspension (NCES) surgery in patients with stable vitiligo.
- Trial name
- NCT07472816
- Testing
- Non-cultured epidermal cell suspension (NCES) surgery, Oral mini pulse, Excimer Sessions
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Vitiligo Vulgaris
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals).
- Trial name
- NCT01206374
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Vitiligo
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life.
- Trial name
- NCT07153666
- Testing
- Ruxolitinib 1.5% Cream BID
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Peking University Third Hospital
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation
Vitiligo
Oral Mini Pulse Dexamethasone in Pediatric Vitiligo
The goal of this clinical trial is to learn if oral mini pulse (OMP) dexamethasone works to treat active vitiligo in children and also learn about the safety of this drug within this age group the main questions it aims to answer…
- Trial name
- NCT07353801
- Testing
- Dexamethasone (0.1 mg/kg)
- Where
- Egypt
- Volunteers
- 22 people
- Sponsor
- Cairo University
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Localized Vitiligo
Efficacy of PRP With Er-YAG Laser Versus With Microneedling in Localized Stable Vitiligo
The aims of this study are to:- Compare the effect of fractional Erbium: YAG laser assisted delivery of platelet- rich plasma versus microneedling with platelet-rich plasma in the induction of skin repigmentation in localized…
- Trial name
- NCT05511493
- Testing
- fractional Erbium-YAG laser, microneedling
- Volunteers
- 40 people
- Sponsor
- South Valley University
Vitiligo
Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of melanocytes in patients with vitiligo.
- Trial name
- NCT00631865
- Testing
- Melanocyte transplantation
- Where
- Iran
- Volunteers
- 300 people
- Sponsor
- Royan Institute
Vitiligo
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
The study will compare the effectiveness of combined treatment with NB-UVB and tacrolimus versus NB-UVB alone . Patients will be treated for 6 months and followed up after 3 months .All types of vitiligo will be included except…
- Trial name
- NCT03199664
- Testing
- NB-UVB, NB-UVB & Tacrolimus 0.03%
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- South Valley University
Vitiligo Vulgaris
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment.
- Trial name
- NCT00372307
- Testing
- Application of pimecrolimus
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- University Hospital, Ghent
Vitiligo
5-fluorouracil for Treatment of Stable Vitiligo
Vitiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. Despite various existing medical approaches, current vitiligo treatments are still far from optimal.
- Trial name
- NCT06209138
- Testing
- 5 fluorouracil, Saline
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Vitiligo, Generalized
Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy
The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2.
- Trial name
- NCT06546059
- Testing
- narrow band ultraviolet-B
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- South Valley University
Non-Segmental Vitiligo
Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China
The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China This study is a cross-sectional…
- Trial name
- NCT07058051
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- AbbVie
Vitiligo Vulgaris
The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo
Vitiligo is an acquired disorder of the skin and mucous membranes characterized by well circumscribed depigmented macules and patches that occur secondary to selective destruction of melanocytes (Zhang et al., 2009).
- Trial name
- NCT03234673
- Testing
- Tacrolimus ointment, calcipotriol ointment, NB-UVB
- Volunteers
- 30 people
- Sponsor
- Assiut University
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
NonSegmental Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
- Trial name
- TRuE-VIP1 (NCT06548360)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 98 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Incyte Corporation
Vitiligo
Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo
Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians.
- Trial name
- NCT05037981
- Volunteers
- 25 people
- Sponsor
- Cairo University